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Methods: We enrolled 248 KD (development dataset: 181, validation: 67) patients who
received IVIG within 10 days after fever onset. IVIG unresponsiveness was defined by persistent
fever beyond 24 hours after IVIG or recrudescent fever with KD symptoms.
Results: From the development dataset (181 patients), IVIG unresponsiveness was noted in 22
patients (12.1%). The preIVIG levels of albumin, percentage of neutrophils, and positive lymph-
adenopathy were identified with highest risk for IVIG unresponsiveness. These three variables
were used to construct a three-variable logistic regression model, which yielded an area under
the receivereoperating-characteristics curve of 0.87. These three variables were further used
to generate a composite scoring model (Formosa score) which yielded a sensitivity of 90.9% and
specificity of 81.3% for a cut-off point of three or more. Validation in an independent cohort
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IVIG Unresponsiveness in Taiwanese KD children 351Conclusion: We have established a simple three-variable Formosa score for KD patients to
identify early those at risk of IVIG unresponsiveness for timely aggressive immunomodulation
initially.
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Kawasaki disease (KD) is the most common pediatric sys-
temic vasculitis. The incidence in Taiwan is the third highest
globally, just lower than that in Japan and Korea.1,2 The
state-of-the-art therapy recommends the intravenous
immunoglobulin (IVIG) therapy during the acute stage,
which is effective to decrease the coronary complications.
In untreated KD patients, coronary arterial lesions (CAL)
with varying severity was noted in 15e25% of the patients.1,2
However, 10e15% of patients may still have persistent or
recurrent fevers after completion of the IVIG therapy, i.e.,
patients with IVIG unresponsiveness. This subgroup of KD
patients is considered more risky to have CAL.3 There are
two treatment strategies for patient with IVIG unrespon-
siveness. One is rescue therapy with a second course of
IVIG,4 steroid,5 infliximab,6 or a combination of the above
medication. The other is add-on therapy, i.e., administra-
tion of IVIG and steroid to certain KD patients who are
considered high risk for being IVIG nonresponders by using a
scoring system, such as the Kobayashi scoring system.3,7e9
However, regional or population differences in such risk
scoring systems are possible and the efficacy needs to be
validated. For example, when we applied the Kobayashi
score to the KD patients in Taiwan,10 we found that the
sensitivity and specificity to predict IVIG unresponsiveness
was only 62% and 71%, respectively. Therefore, this study
aimed to identify the risk factors from the clinical and lab-
oratory parameters of our cohort and to construct a novel
risk scoring system (Formosa score) for an early detection of
the KD patients with IVIG unresponsiveness.
Materials and methods
The study was approved by National Taiwan University Hos-
pital Institutional Research Board (NTUHREC-201411077 RIN).
Patients
We enrolled patients with KD who had at least five of the
following six manifestations1,11: fever for> 5 days, skin rash,
neck lymphadenopathy, nonpurulent bulbar conjunctivitis,
red lip with fissure and/or strawberry tongue, and palm/sole
erythema and induration followed by desquamation. We also
enrolled patients with incomplete KD, defined as occurring in
patients who had less than five of the above manifestations
but who had a coronary arterial abnormality. Those KD pa-
tients who were admitted to our institution (developmentdataset: between January 2009 and December 2012; valida-
tion dataset: between January 2013 and June 2014) and
administered IVIG (2 g/Kg 1 day or 1 g/Kg 2 days)within 10
days after fever onsetwere enrolled as development dataset.
The 1st day of the illnesswas defined as the dayof fever onset.
Patients were considered afebrile when their body temper-
ature at theaxilla remained< 37.5C for> 24 hours. The dose
of aspirin was decreased to 5 mg/kg/d after fever subsided.
Medical records were reviewed and the details of the mani-
festations, including the six principal symptoms, i.e., fever,
polymorphous exanthema, changes in extremities (ery-
thema, edema, and peeling), bulbar conjunctivitis, changes
of lips and oral cavity (red lip, strawberry tongue, and in-
jection of oral mucosa), and cervical lymphadenopathy, as
well as the erythematous changes at Bacillus Calmette-Gue´-
rin (BCG) inoculation site were collected. Laboratory data
including blood cell count, urinary analysis, levels of albumin
and aspartate aminotransferase, and acute phase reactants
during the acute phase were obtained. All children received
echocardiography during the febrile stage and the subacute
phase (1 week, 3 weeks, 6 weeks, and 3 months after fever
onset, and the subsequent frequency varieddependingon the
severity of the CAL).
IVIG unresponsiveness was defined if, after the
completion of the first course of IVIG, patients had fever
persistent for > 24 hours or developed recrudescent fever
associated with KD symptoms after an afebrile period.1,4,11
From January of 2013 to June of 2014, a validation dataset
of additional 67 KD patients were studied prospectively to
test the accuracy of prediction.
Coronary arterial abnormalities were defined whenever
body surface area-adjusted z-score of any coronary ves-
sels12 was  þ2.5, including left main coronary artery, left
anterior descending artery, and right coronary artery.
Statistical analysis
We performed analyses using SPSS version 18 (SPSS Inc.,
Chicago, IL, USA). The data were expressed as
mean  standard deviation (medians with ranges), and
percentages for categorical data we used Student t test for
comparisons of numerical data. The Chi-square test was
used to compare categorical data. Variables related to re-
fractory events with p < 0.1 in the univariate analysis were
entered into the multivariate model. Multivariate logistic
regression model was conducted to evaluate the association
of multiple risk factors with IVIG unresponsiveness. Results
are expressed as a hazard ratio with a 95% confidence in-
terval (CI). Statistical significance was set at p < 0.05.
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Characteristics and clinical outcomes of patients
During the study period, 248 (development dataset: 181,
validation: 67) patients were enrolled and 29 (11.7%) of
them (Male:Female Z 1.41:1) were KD patients with IVIG
unresponsiveness. Coronary artery abnormalities developed
in 40 (16.1%) of all the enrolled patients.Univariate and multivariate analysis
Development dataset (181 children, January
2009eDecember 2012)
From the development dataset, we noted 22 (12.1%) pa-
tients with IVIG unresponsiveness. From the liter-
ature,3,7e9,11e17 we picked up the following demographic
and laboratory variables for analysis, including age (in
years), gender, occurrence of skin rash, conjunctivitis, oral
presentations, palm edema, lymphadenopathy or red halo
of BCG inoculation, platelet count, percentage of neutrophil
and levels of hemoglobin, albumin, sodium, aspatate
aminotransferase (AST), and C reactive protein (CRP). Uni-
variate analysis to compare the IVIG responders with non-
responders revealed three laboratory variables (albumin,
neutrophil percentage, and CRP) and lymphadenopathy as
significant risk factors of IVIG unresponsiveness (Table 1).
To avoid the confounding effects, we conducted corre-
lation studies on the three laboratory variables with sig-
nificant association with IVIG unresponsiveness, including
albumin, neutrophil (%), and CRP. The correlation co-
efficients were 0.34 (for the association between albumin
and CRP) and 0.38 (for the association between neutro-
phil and CRP), respectively (both p < 103). Therefore, we
included levels of albumin, and percentage of neutrophil
and lymphadenopathy in the following multivariateTable 1 Comparison between IVIG responders and nonresponde
Case no. IVIG nonresponder (n Z 22)
Age (y) 181 1.9  1.4
Male sex 181 11 (50)
Albumin (g/dL) 145 3.3  0.8
Na (mmol/L) 179 130.2  27.2
AST (U/L) 181 113.9  314.2
Neutrophil (%) 181 72.7  10.6
CRP (mg/dL) 181 13.8  7.6
PLT (K/mL) 181 294.8  119.9
Hb (g/dL) 181 10.7  1.2
LAP 181 14 (63.6)
Skin rash 181 22 (100)
Conjunctivitis 181 17 (77.3)
Palm edema 181 10 (45.5)
Oral presentation 181 20 (90.9)
Data are presented as n (%) or mean  SD.
AST Z aspatate aminotransferase; CRPZ C reactive protein; Hb Z
disease; LAP Z positive lymphadenopathy; N/A Z not available; Na
Bold front means statistically significant (<0.05).analysis. Multivariate logistic regression showed low levels
of albumin (hazard ratio: 6.1, 95% CI: 1.7e21.7, pZ 0.005)
and occurrence of lymphadenopathy (positive lymphade-
nopathy, hazard ratio: 3.8, 95% CI: 1.1e13.5, p Z 0.037)
were proved to be independent risk factors of IVIG unre-
sponsiveness. The association of neutrophil percentage
with IVIG unresponsiveness was borderline significant
(hazard ratio: 8.1, 95% CI: 0.96e68.72, p Z 0.055). The
area under the receiver operating characteristic (ROC)
curve was 0.87 (95% confidence interval: 0.76e0.97), rep-
resenting competent discrimination. For a cut-off proba-
bility of 0.197, sensitivity and specificity in prediction of
IVIG unresponsiveness were 86.7% and 80.8%, respectively.
We then constructed a composite scoring model, For-
mosa score, to increase the efficacy of risk stratification
based on the information from logistic regression analysis.
Cut-off points and score points for each variable were as
follows: albumin < 3.5 g/dL, 1 point; neutrophil percentage
 60%, 2 points; and positive lymphadenopathy, 1 point.
The median score for the study population was 2 (range,
0e4). Ten IVIG-responsive KD patients did not receive a test
for albumin levels. Therefore, 172 patients entered into the
scoring analysis. The area under the ROC curve was 0.86
(95% CI, 0.76e0.97) for the risk scoring model. For
simplicity, two risk subgroups were identified: low risk,
with score of 0e2, covering 72.1% of patients; high risk,
with scores of 3 or 4. The sensitivity and specificity were
90.9% and 81.3%, respectively. In the high risk group
(scores  3), the occurrence of IVIG unresponsiveness was
41.7%, whereas it was only 1.6% in the low risk group (scores
0e2). Especially in those with very high score (scoresZ 4),
50% of such patients were refractory to IVIG (Fig. 1).
Validation dataset (67 children, January 2013eJune
2014)
The validation dataset was used to assess how accurate the
Formosa score was in identifying patients with IVIGrs in the 181 KD patients of the development dataset.
IVIG responder (n Z 159) Univariate analysis
OR (95%CI) p
1.9  1.8 0.98 (0.75,1.27) 0.86
96 (60) 1.50 (0.61,3.67) 0.37
4  0.5 0.14 (0.04,0.43) 0.0006
136.1  4.1 0.97 (0.92,1.01) 0.16
90.1  160 1.001 (0.99,1.003) 0.59
61  15.7 1.06 (1.02,1.10) 0.0016
7.9  6.1 1.13 (1.06,1.20) 0.0003
348.7  128 0.99 (0.99,1.00) 0.06
11.2  1.3 0.74 (0.52,1.06) 0.1
35 (22.6) 6 (2.33,15.47) 0.0002
139 (89.1) N/A 0.08
136 (87.2) 0.50 (0.17,1.51) 0.22
62 (39.7) 1.26 (0.52,3.10) 0.61
128 (82.6) 2.11 (0.47,9.56) 0.33
hemoglobin; IVIG Z intravenous immunoglobulin; KDZ Kawasaki
Z sodium; PLT: platelet count.
Figure 1 Simple scoring (Formosa score) model evaluated for
correspondence with IVIG unresponsiveness in the develop-
ment datasets. IVIG Z intravenous immunoglobulin.
Figure 3 Simple scoring (Formosa score) model evaluated for
correspondence with IVIG unresponsiveness in the develop-
ment and validation datasets. IVIG Z intravenous
immunoglobulin.
IVIG Unresponsiveness in Taiwanese KD children 353unresponsiveness. IVIG unresponsiveness was noted in 7
(10.4%) out of 67 KD patients (Male:Female Z 40:27)
admitted to our institution between January 2013 and June
2014. Applying the Formosa score to predict the IVIG unre-
sponsiveness in this validation dataset, the sensitivity and
specificity were 71.4% and 81.0%, respectively. The positive
and negative predictive values were 31.3% and 95.9%,
respectively.
Overall dataset (248 patients)
Taking the 248 patients from the development and valida-
tion dataset together, the recalculation revealed the
sensitivity and specificity of Formosa score were 86.2% (25/
29) and 81.3% (170/209), respectively.
All of the 29 KD patients with IVIG unresponsiveness
received a second course of IVIG therapies (2 g/kg) and 23
of them (81.8%) defervesced. Four patients had a third dose
of IVIG and the other two had methylprednisolone (30 mg/
kg/d  3days) in addition to IVIG.Figure 2 Simple scoring (Formosa score) model evaluated for
correspondence with coronary arterial lesions (CAL) in the
development datasets.Coronary arterial abnormalities (z scoreþ2.5) devel-
oped significantly more often in those with IVIG unre-
sponsiveness than in responders (12/29 vs. 28/219,
p < 0.01). Observed rates of CAL occurrence based on this
simple scoring system are plotted in Fig. 2. The occurrence
of CAL was 21.3% and 15.2% in the high (score  3) and low
risk (score < 3) groups, respectively (c2Z 2.56, pZ 0.11).
For those KD patients with scores of 4, the risk of IVIG
unresponsiveness and CAL was extremely high (50% and
25%, Figs. 2 and 3).Discussion
In this study, we describe a novel prediction model for KD
patients to identify IVIG unresponsiveness. We found that
KD patients with four clinical and laboratory risk factors
(levels of albumin, neutrophil percentage, CRP, and
lymphadenopathy) are more likely refractory to the first
course of IVIG therapy. At developing the prediction model,
the CRP level was omitted due to a compounding role.
Simple cut-off points and a composite Formosa scoring are
effective and can be used to define high and low risk groups
for IVIG unresponsiveness.
Several scoring models had been developed previously to
predict IVIG unresponsiveness and are listed in Table 2.
Most of the previous scoring systems were based on age,
hematological, hepatobiliary, and inflammatory biomarkers
as risk variables. In the present study, other than the
neutrophil percentage, we incorporated two parameters,
hypoalbuminemia and lymphadenopathy, into the calcula-
tion of the novel Formosa score. Lower albumin levels have
been linked to refractory KD patients13e15 and may reflect
higher degrees of inflammation and vascular leakage. Terai
et al14 reported that the KD patients with IVIG unrespon-
siveness had higher levels of vascular endothelial growth
factor, which might lead to vascular leakage, reduced al-
bumin levels, and pericardial effusion.18 Durongpisitkul
et al16 also showed that refractory KD patients had the
following risk factors: hemoglobin < 10 g/dL, neutrophil >
Table 2 Scoring systems to predict IVIG-resistance in the patients with Kawasaki disease.
Nation Scoring
system
Enrolled
KD no.
No. of
IVIG-resistant
Risk factors Sensitivity (%) Specificity (%) Positive
predictive
value
Negative
predictive
value
Japan Fukunishi
score9
82 13 CRP > 10 mg/dL 84.6 87.0 55.0% 96.8%
LDH > 590 IU/L
Hb < 11 g/dL
Egami
score8
320 41 Age < 6 mo 78.0 76.0 32.3% 95.9%
Illness days 4 d
CRP  8 mg/dL
ALT  80 IU/L
PLT 30  104/mm3
Kobayashi
score3
528 148 Age  12 mo 86.0 68.0 51.0% 92.5%
Illness days  4 d
CRP  10 mg/dL
AST  100 IU/L
PLT  30  104/mm3
Sodium  133 mmol/L
%Neutrophil  80%
America San Diego
score7
362 60 Illness days 4 d 73.3 61.9 27.7% 92.1%
GGT  60 IU/L
%bands  20%
ZHb  2
Taiwan Formosa
score
248 29 Positive lymphadenopathy % 86.2 81.3 39.1% 97.7%
Neutrophil  60%
Albumin < 3.5 g/dL
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; CRPZ C reactive protein; GGT Z Gamma-glutamyl trans-
peptidase; Hb Z hemoglobin; IVIG Z intravenous immunoglobulin; KDZ Kawasaki disease; LDH Z lactate dehydrogenase;
PLT Z platelet count; ZHb Z z value of hemoglobin.
354 M.-T. Lin et al.75%, and lower albumin levels. In this study, the hemoglo-
bin levels of IVIG-unresponsive KD patients were borderline
lower than those IVIG responders (p Z 0.06).
In the validation dataset, the sensitivity and positive
predictive value both declined > 10%, compared with those
in the development dataset. There were two possible rea-
sons for the phenomenon: (1) relatively small case number
of our validatation dataset; and (2) our hospital is a tertiary
medical center and w20e30% of KD patients are cases of
referral. Both factors might result in selection bias, such as
disease severity. In addition, we scored those with per-
centage of neutrophils > 60% as 2 points because of the
high odds ratio (8.1) for this factor. However, its statistical
significance was borderline (p Z 0.055). Therefore, selec-
tion bias generated from small validation dataset may un-
expectedly magnify the effects of neutrophil percentages
and then compromise the performance of Formosa score.
Muta et al17 found that cervical lymphadenopathy was
one of independent risk factors of IVIG unresponsiveness
(odds ratio: 1.89, 95% CI: 1.66e2.16). However, two other
studies, did not demonstrate the correlation of IVIG unre-
sponsiveness with lymphadenopathy.15,19 Microscopic ex-
aminations of the lymph node of the KD patients18 showed
hyperplastic germinal center full of lymphocytes and large
atypical mononuclear cells. Therefore, positive lymphade-
nopathy might be also an indicator of a high degree of
inflammation.
Another popular Japanese scoring models, Kobayashi
score,3 enrolled variables of AST, CRP, % of neutrophils, lowage in months, sodium level, platelet count, and early
administration of IVIG, to predict IVIG unresponsiveness.
When we applied Kobayashi score system to the KD patients
in Taiwan, the sensitivity was only 61%. The reasons for
such a difference could be due to genetic difference and
some other environmental factors. For example, the allelic
distribution of rs28493229 (one of ITPKC genetic variants
associated with KD occurrence) was significantly different
between Japan and Taiwan (8% vs. 4.3%).20 The regulation
of health insurance reimbursement can be another impor-
tant impact factor. In Taiwan, the national health insurance
covered 99.8% of population (2) and the administration of
IVIG can be started only after at least 5 days after fever
onset. That may lead to underscoring of “illness days  4
days” at the application of Kobayashi scores to Taiwanese
KD patients. Therefore, the scoring system to identify high
risk for IVIG unresponsiveness needs to be tailored to indi-
vidual populations.
Hepatobiliary dysfunction and its association with IVIG
unresponsiveness6,21 and the development of CAL10,21 in KD
patients have been described before. The mechanism still
remains unclear, and could be due to generalized inflam-
mation, vasculitis of small and medium-sized vessels, toxin
mediated effects, or a combination of the above.21,22 Pre-
vious pathology studies have demonstrated the presence of
vasculitis in the liver of six/37 KD patients autopsied.18
Inflammatory cell infiltration in the sinusoids and portal
areas and proliferation of Kupffer cells were also
described.23 Together with the above, abnormal liver
IVIG Unresponsiveness in Taiwanese KD children 355function might indicate enhanced inflammation associated
with relatively poor response to IVIG. In the current study,
we found that AST levels were not significantly different
between IVIG responders and nonresponder’s (Table 1) and
adding AST as a variable together with albumin, neutrophil
percentage, and lymphadenopathy into the scoring system
was not superior to the 3-variable score.
The current Formosa score, though is effective to pre-
dict the IVIG unresponsiveness, is not a sensitive predictor
for coronary severity. IVIG unresponsiveness has been
shown to increase the coronary risk in KD patients.3,7 It is
likely that there are additional coronary risk factors other
than the IVIG unresponsiveness. The differences between
the risk-scoring for IVIG responsiveness and the coronary
severity in Taiwanese KD patients need to be clarified by
future studies.
This study had several limitations. (1) This was a study
conducted in a tertiary medical center, therefore, selection
bias might occur such as severity of KD cases. (2) We did not
conduct stringent validation by using an independent KD
cohort from other institutions, thus, application of the
model to the general population should be careful.
In conclusion, our predictive models based on the clin-
ical and laboratory variables correlated well to IVIG unre-
sponsiveness in the initial treatment of KD patients. The
model may provide valuable messages for making decisions
regarding the therapeutic modalities on the KD patients.Acknowledgments
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